Close

SAGE Therapeutics (SAGE) Prices 4.4M Common Stock Offering at $39.75/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/18/2024

1. LVS
2. TSM
3. SPY
4. CSX
5. AA
6. BPTS
7. EFX
8. ORCL
9. NRXP
10. CCI


Go back to SAGE Therapeutics (SAGE) Prices 4.4M Common Stock Offering at $39.75/Share

Sage Therapeutics Announces Pricing of Public Offering of Common Stock

September 8, 2016 8:51 PM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the pricing of an underwritten public offering of 4,402,515 shares of its common stock at a public offering price of $39.75 per share, before underwriting discounts. In addition, Sage has granted the underwriters a 30-day option to purchase up to an additional 660,377 shares of its common stock.

J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint book-running managers for the offering. Cowen and Company,... More

Sage Therapeutics Announces Proposed Public Offering of Common Stock

September 7, 2016 4:01 PM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $150.0 million of its common stock. Sage also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its common stock offered in the public offering. All of the shares in the offering are to be sold by Sage.

J.P. Morgan Securities LLC and Goldman, Sachs & Co. are acting as joint... More